Celsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Tuesday

Celsion Corporation (NASDAQ:CLSN) will issue its quarterly earnings data before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Celsion Corporation (CLSN) opened at $2.00 on Monday. Celsion Corporation has a 12 month low of $1.24 and a 12 month high of $12.88.

WARNING: “Celsion Corporation (CLSN) Scheduled to Post Quarterly Earnings on Tuesday” was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/11/13/celsion-corporation-clsn-scheduled-to-post-quarterly-earnings-on-tuesday.html.

CLSN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, August 29th. Maxim Group upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $12.63.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Earnings History for Celsion Corporation (NASDAQ:CLSN)

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply